The DOI matches its Crossref record.
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells.
Abstract
CD30 has been extensively studied as a cell surface marker expressed by Reed-Sternberg cells of Hodgkin's disease and other hematologic malignancies, although little is known about its expression by normal lymphoid cells. We therefore characterized the requirements for the induction of CD30 expression and identified the subsets of T cells that express CD30. CD30 is inducible on approximately 15% of normal PBMC stimulated with any of a variety of nonspecific T cell activators, including PHA, Con A, anti-T11(2) + T11(3), and anti-CD3; ionomycin alone induced lower percentages of CD30+ T cells (3 +/- 2%) compared to other stimuli. Maximal numbers of CD30+ cells were observed at 48 to 72 h of activation and the addition of rIL-2 did not affect these kinetics. However, CD30 expression was enhanced by the addition of exogenous rIL-2 to any of the stimuli tested, although rIL-2 alone did not lead to CD30 expression. The induction of CD30 during anti-CD3 mitogenesis was completely inhibitable by anti-IL-2 antibodies and partially inhibitable by rIL-4, indicating a requirement for both TCR triggering and IL-2 for its expression. Dual immunofluorescence analysis revealed that CD30+ cells were confined to CD3+ T cells that coexpressed higher levels of the p55 IL-2 receptor (CD25) than the CD30- population. Furthermore, CD30 expression was restricted to a subset of cells derived from CD45RO+ T cell precursors. Cell cycle analysis showed that CD30+ expression was not cell cycle dependent. Cross-linking of membrane CD30 induced Ca2+ in TCR+, but not TCR- Jurkat T cells. These results demonstrate that CD30 can serve as a T cell signal-transducing molecule and expressed by a unique subset of activated CD45RO+ T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1148 · Cited by 863
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
Lucey, D. R., Clerici, M., & Shearer, G. M. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.532 · Cited by 666
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Falini, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, L., Stirpe, F., Martelli, M., & Stein, H. (1995) · Blood · doi:10.1182/blood.v85.1.1.bloodjournal8511 · Cited by 441
Biology of human TH1 and TH2 cells
Romagnani, S. (1995) · Journal of Clinical Immunology · doi:10.1007/bf01543103 · Cited by 406
Decker, D., Schöndorf, M., Bidlingmaier, F., Hirner, A., & von Ruecker, A. A. (1996) · Surgery · doi:10.1016/s0039-6060(96)80118-8 · Cited by 385
von Bülow, G.-U., & Bram, R. J. (1997) · Science · doi:10.1126/science.278.5335.138 · Cited by 372
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice
Amakawa, R., Hakem, A., Kundig, T. M., Matsuyama, T., Simard, J. J. L., Timms, E., Wakeham, A., Mittruecker, H.-W., Griesser, H., Takimoto, H., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81031-4 · Cited by 305
Translocations involving anaplastic lymphoma kinase (ALK)
Duyster, J., Bai, R.-Y., & Morris, S. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204594 · Cited by 279
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
Lam, J. H., Hong, M., Koo, S.-L., Chua, C. W. L., Lim, K. L., Wee, F., Wan, W. K., Leow, W. Q., Yeo, J. G., Tan, I. B. H., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02859-x · Cited by 31
Metadata
- Authors
- Ellis, T. M., Simms, P. E., Slivnick, D. J., Jäck, H. M., & Fisher, R. I.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1993-09-01
- Volume
- 151
- Issue
- 5
- Pages
- 2380-2389
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1526820115
- Cited by
- 203
- References
- 0
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.